Drug Profile
REGN 1154
Alternative Names: REGN-1154Latest Information Update: 26 May 2016
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; Sanofi
- Developer Regeneron Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 30 Jan 2014 Phase-I development is ongoing
- 25 Jan 2013 Regeneron Pharmaceuticals completes enrolment in its phase I trial in Healthy volunteers in Australia (NCT01540539)
- 31 Mar 2012 Phase-I clinical trials in Undefined indication in Australia (IV)